-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 28, Yichang Renfu Pharmaceutical submitted a new drug listing application for isoflurane injection 2.
2.
Isoflurane can be used for the induction and maintenance of general anesthesia.
At present, there is no injection form on the market, and Renfu is the first to report for production
.
In recent years, Renfu Medicine has aggressively attacked improved new drugs.
In addition to isoflurane injection, there are 7 improved new drugs that have attracted market attention
.
2.
Isoflurane can be used for the induction and maintenance of general anesthesia.
At present, there is no injection form on the market, and Renfu is the first to report for production
.
In recent years, Renfu Medicine has aggressively attacked improved new drugs.
In addition to isoflurane injection, there are 7 improved new drugs that have attracted market attention
.
Figure 1: The latest products declared by Renfu
Source: CDE official website
Figure 2: Current status of companies that have obtained isoflurane approvals
Source: One-click retrieval from Minet
Isoflurane is a general anesthetic.
According to Minet.
com data, in the first half of 2021 , among the TOP20 terminal general anesthetics in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions), isoflurane.
Halothane ranks in the TOP10, and only 5 companies have been approved ( including 1 import company).
Currently, no injections and other dosage forms have been approved
.
According to Minet.
com data, in the first half of 2021 , among the TOP20 terminal general anesthetics in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions), isoflurane.
Halothane ranks in the TOP10, and only 5 companies have been approved ( including 1 import company).
Currently, no injections and other dosage forms have been approved
.
Table 1: Application status of new improved drugs of Renfu Medicine since 2019 (excluding new indications of category 2.
4)
4)
Source: Minet China Drug Clinical Trials Publicity Library
Since 2019, Renfu Medicine has applied for a total of 8 new improved drugs, among which isoflurane injection has applied for marketing and is under review, dexmedetomidine transdermal patch (II) has applied for clinical application and is under review, and Shufen/Tai/ The transdermal patch and dexmedetomidine transdermal patch are undergoing Phase I clinical trials, and the remaining 4 have also obtained clinical approvals
.
.
From the perspective of indications, the improved new drugs of Renfu Medicine all involve the field of anesthesia and analgesia
.
With the completion of clinical trials of these new products and the successive reports for production, Renfu Medicine will further enrich the product layout of Renfu Medicine in the field of anesthesia and analgesia after the launch, and is expected to continue to strengthen the company's market leadership
.
.
With the completion of clinical trials of these new products and the successive reports for production, Renfu Medicine will further enrich the product layout of Renfu Medicine in the field of anesthesia and analgesia after the launch, and is expected to continue to strengthen the company's market leadership
.
On February 28, Yichang Renfu Pharmaceutical submitted a new drug listing application for isoflurane injection 2.
2.
Isoflurane can be used for the induction and maintenance of general anesthesia.
At present, there is no injection form on the market, and Renfu is the first to report for production
.
In recent years, Renfu Medicine has aggressively attacked improved new drugs.
In addition to isoflurane injection, there are 7 improved new drugs that have attracted market attention
.
2.
Isoflurane can be used for the induction and maintenance of general anesthesia.
At present, there is no injection form on the market, and Renfu is the first to report for production
.
In recent years, Renfu Medicine has aggressively attacked improved new drugs.
In addition to isoflurane injection, there are 7 improved new drugs that have attracted market attention
.
Figure 1: The latest products declared by Renfu
Source: CDE official website
Figure 2: Current status of companies that have obtained isoflurane approvals
Source: One-click retrieval from Minet
Isoflurane is a general anesthetic.
According to Minet.
com data, in the first half of 2021 , among the TOP20 terminal general anesthetics in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions), isoflurane.
Halothane ranks in the TOP10, and only 5 companies have been approved ( including 1 import company).
Currently, no injections and other dosage forms have been approved
.
According to Minet.
com data, in the first half of 2021 , among the TOP20 terminal general anesthetics in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions), isoflurane.
Halothane ranks in the TOP10, and only 5 companies have been approved ( including 1 import company).
Currently, no injections and other dosage forms have been approved
.
Table 1: Application status of new improved drugs of Renfu Medicine since 2019 (excluding new indications of category 2.
4)
4)
Source: Minet China Drug Clinical Trials Publicity Library
Since 2019, Renfu Medicine has applied for a total of 8 new improved drugs, among which isoflurane injection has applied for marketing and is under review, dexmedetomidine transdermal patch (II) has applied for clinical application and is under review, and Shufen/Tai/ The transdermal patch and dexmedetomidine transdermal patch are undergoing Phase I clinical trials, and the remaining 4 have also obtained clinical approvals
.
.
From the perspective of indications, the improved new drugs of Renfu Medicine all involve the field of anesthesia and analgesia
.
With the completion of clinical trials of these new products and the successive reports for production, Renfu Medicine will further enrich the product layout of Renfu Medicine in the field of anesthesia and analgesia after the launch, and is expected to continue to strengthen the company's market leadership
.
.
With the completion of clinical trials of these new products and the successive reports for production, Renfu Medicine will further enrich the product layout of Renfu Medicine in the field of anesthesia and analgesia after the launch, and is expected to continue to strengthen the company's market leadership
.
On February 28, Yichang Renfu Pharmaceutical submitted a new drug listing application for isoflurane injection 2.
2.
Isoflurane can be used for the induction and maintenance of general anesthesia.
At present, there is no injection form on the market, and Renfu is the first to report for production
.
In recent years, Renfu Medicine has aggressively attacked improved new drugs.
In addition to isoflurane injection, there are 7 improved new drugs that have attracted market attention
.
2.
Isoflurane can be used for the induction and maintenance of general anesthesia.
At present, there is no injection form on the market, and Renfu is the first to report for production
.
In recent years, Renfu Medicine has aggressively attacked improved new drugs.
In addition to isoflurane injection, there are 7 improved new drugs that have attracted market attention
.
Figure 1: The latest products declared by Renfu
Source: CDE official website
Figure 2: Current status of companies that have obtained isoflurane approvals
Source: One-click retrieval from Minet
Isoflurane is a general anesthetic.
According to Minet.
com data, in the first half of 2021 , among the TOP20 terminal general anesthetics in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions), isoflurane.
Halothane ranks in the TOP10, and only 5 companies have been approved ( including 1 import company).
Currently, no injections and other dosage forms have been approved
.
Hospital Hospital Hospital Enterprise Enterprise EnterpriseAccording to Minet.
com data, in the first half of 2021 , among the TOP20 terminal general anesthetics in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions), isoflurane.
Halothane ranks in the TOP10, and only 5 companies have been approved ( including 1 import company).
Currently, no injections and other dosage forms have been approved
.
Table 1: Application status of new improved drugs of Renfu Medicine since 2019 (excluding new indications of category 2.
4)
medicine medicine medicine4)
Source: Minet China Drug Clinical Trials Publicity Library
Since 2019, Renfu Medicine has applied for a total of 8 new improved drugs, among which isoflurane injection has applied for marketing and is under review, dexmedetomidine transdermal patch (II) has applied for clinical application and is under review, and Shufen/Tai/ The transdermal patch and dexmedetomidine transdermal patch are undergoing Phase I clinical trials, and the remaining 4 have also obtained clinical approvals
.
.
From the perspective of indications, the improved new drugs of Renfu Medicine all involve the field of anesthesia and analgesia
.
With the completion of clinical trials of these new products and the successive reports for production, Renfu Medicine will further enrich the product layout of Renfu Medicine in the field of anesthesia and analgesia after the launch, and is expected to continue to strengthen the company's market leadership
.
.
With the completion of clinical trials of these new products and the successive reports for production, Renfu Medicine will further enrich the product layout of Renfu Medicine in the field of anesthesia and analgesia after the launch, and is expected to continue to strengthen the company's market leadership
.
